Guggenheim has recently reduced ACADIA Pharmaceuticals Inc (ACAD) stock to Neutral rating, as announced on January 3, 2025, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed ...

Fintel reports that on January 3, 2025, Guggenheim downgraded their outlook for ACADIA Pharmaceuticals (NasdaqGS:ACAD) from ...

As previously reported, Guggenheim downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a price target of $20, down from $23. The ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating ...

Guggenheim analyst Yatin Suneja downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a $20 price target Don't Miss Our New Year's ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a modest uptick, ending the day at $18.35 which represents a slight increase of $1.66 or 9.95% from the prior close of $16.69. The stock opened at $18.24 ...

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw a significant decrease in short interest during the month of ...

Acadia’s 50-day moving average is in the process of crossing above the stock’s 200-day moving average. This crossover forms a ...

Shares of Acadia Pharmaceuticals rose after the company said it was set to join the S&P SmallCap 600 index. The biopharmaceutical company's stock jumped 12% to $18.73 in morning trading Tuesday, ...

Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective ...

On the final trading day of 2024, US stock futures were mainly lower following a third straight drop in Wall Street's S&P 500 ...